BAJAJ BROKING

Notification close image
No new Notification messages
card image
Oswal Pumps IPO is Open!
Apply for the Oswal Pumps IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

Biocon Q4 Results FY24-25: Net Profit Surges 153%, Revenue Up 12% YoY

Synopsis:

Biocon posted a strong Q4 FY25 with consolidated net profit rising 153% YoY to Rs.344 crore. Revenue from operations increased 12% to Rs.4,454 crore. The board approved a final dividend of Rs.0.50 per share for FY25.

Overview and performance summary

Biocon delivered a robust Q4 FY25 performance, driven by its biosimilars and generics businesses. Consolidated net profit rose sharply by 153% year-on-year to Rs.344 crore, up from Rs.136 crore in Q4 FY24. Revenue from operations reached Rs.4,454 crore, reflecting a 12% increase over the same quarter last year.

Group core EBITDA stood at Rs.1,363 crore, up 16% YoY, with a core operating margin of 31%. Overall EBITDA was reported at Rs.1,115 crore, also up 16%, with a margin of 25%. The company declared a final dividend of Rs.0.50 per share, representing 10% of the face value.

BIOCON LIMITED.

Trade

355.43.14 (0.89 %)

Updated - 13 June 2025
357.90day high
DAY HIGH
345.00day low
DAY LOW
8013966
VOLUME (BSE)

Key highlights and takeaways

  • Q4 FY25 net profit surged 153% YoY to Rs.344 crore from Rs.136 crore.

  • Revenue from operations rose 12% YoY to Rs.4,454 crore.

  • Core EBITDA for the quarter stood at Rs.1,363 crore; margin at 31%.

  • Final dividend of Rs.0.50 per share recommended for FY25.

  • Board approved fund-raising of up to Rs.4,500 crore through multiple routes.

Management commentary and strategic outlook

Biocon marked its entry into the GLP-1 therapy segment with the UK launch of Liraglutide, expanding its therapeutic reach. Its biosimilars segment remained a global growth driver, with four products crossing the $200 million mark in sales. Syngene's acquisition of a biologics manufacturing facility in the US further strengthens its capabilities.

Looking ahead, Biocon aims to scale its GLP-1 portfolio, expand into new markets, and improve API business efficiency with new capacities and cost optimisation in FY26.

Sector expectations and business outlook

The biopharma sector is poised for innovation-led growth, driven by rising biosimilar adoption, new molecule launches, and healthcare demand. Biocon’s strategic investments in biologics, global manufacturing, and differentiated generics position it favourably to capitalise on industry tailwinds and global market expansion.

Biocon consolidated financial table

Metric

Q4 FY25

Q4 FY24

FY25 (Est.)

FY24 (Est.)

Revenue from operations (Rs. Cr)

4,454

3,975

16,470

15,695

Net profit (Rs. Cr)

344

136

1,013

1,022

Core EBITDA (Rs. Cr)

1,363

1,175

Core operating margin

31%

Dividend per share (Rs.)

0.50

0.50

Fund-raising approved

Rs.4,500 Cr

Source: Biocon Ltd – Board Meeting Outcome and Audited Q4 FY25 Financial Results

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://www.bajajbroking.in/disclaimer

Share this article: 

Read More Blogs

Disclaimer :

The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.

The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.

Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.

BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.

Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

[ Read More ]

For more disclaimer, check here : https://www.bajajbroking.in/disclaimer

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

10 lakh+ Users

icon-with-text

4.4 App Rating

icon-with-text

4 Languages

icon-with-text

₹5100+ Cr MTF Book

icon-with-text